MAP0004: Dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 13, 2012, Pages 1961-1968

  Silberstein, Stephen ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Efficacy; Ergotamine; Pulmonary delivery; Serotonin; Tolerability; Vasoconstrictive effects

Indexed keywords

ADRENERGIC RECEPTOR; ALMOTRIPTAN; DIHYDROERGOTAMINE; DIHYDROERGOTAMINE MESILATE; DOMPERIDONE; DOPAMINE RECEPTOR; DRUG METABOLITE; ELETRIPTAN; ERGOTAMINE; ERGOTAMINE TARTRATE; MAP 0004; METOCLOPRAMIDE; NARATRIPTAN; PARACETAMOL; PLACEBO; RIZATRIPTAN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SUMATRIPTAN; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

AEROSOL; AREA UNDER THE CURVE; ARTERY CONSTRICTION; ARTICLE; CHILL; DIZZINESS; DRUG BINDING; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUSHING; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; HUMAN; HYPESTHESIA; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; MIGRAINE; MUSCLE TIGHTNESS; NAUSEA AND VOMITING; PARESTHESIA; PAROSMIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; UTERUS CONTRACTION; VENOCONSTRICTION;

ADMINISTRATION, INHALATION; ANIMALS; DIHYDROERGOTAMINE; DOPAMINE AGONISTS; DRUG DELIVERY SYSTEMS; HUMANS; METERED DOSE INHALERS; MIGRAINE DISORDERS; PULMONARY ALVEOLI; VASOCONSTRICTOR AGENTS;

EID: 84865311089     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.711319     Document Type: Article

References (33)

1. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193-210 (Pubitemid 46354128)
2. Buse DC, Rupnow MF, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 2009;84:422-35
3. Smitherman TA, McDermott MJ, Bachanan EM. Negative impact of episodic migraine on a university population: quality of life, functional impairment, and comorbid psychiatric symptoms. Headache 2011;51:581-9
4. Stewart WF, Wood GC, Manack A, et al. Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med 2010;52:8-14
5. Dahlöf CG. Infrequent or non-response to oral sumatriptan does not predict response to other triptans-review of four trials. Cephalalgia 2006;26:98-106
6. Lantéri-Minet M. Clinical use of triptans in the management of migraine. CNS Drugs 2006;20(spec no. 1):12-23
7. Velati D, Viana M, Cresta S, et al. 5-hydroxytryptamine1B receptor and triptan response in migraine, lack of association with common polymorphisms. Eur J Pharmacol 2008;580:43-7
8. Horton BT, Peters GA, Blumenthal LS. A new product in the treatment of migraine: a preliminary report. Mayo Clin Proc 1945;20:241-8
9. Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia 2008;28:877-86
10. Lipton RB. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache 1997;37(Suppl 1):S33-41
11. Bigal ME, Tepper SJ. Ergotamine and dihydroergotamine: a review. Curr Pain Headache Rep 2003;7:55-62 (Pubitemid 38915071)
12. Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache 1997;37(Suppl 1):S15-25
13. Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 2003;43:144-66 (Pubitemid 36188447)
14. Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache centre-clinical characteristics and treatment outcomes. Cephalalgia 2004;24:483-90 (Pubitemid 38748030)
15. Zidverc-Trajkovic J, Pekmezovic T, Jovanvic Z, et al. Medication overuse headache: clinical features predicting treatment outcome at 1-year follow-up. Cephalalgia 2007;27:1219-25 (Pubitemid 47631900)
16. Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 2006;46(Suppl 4):S171-81 (Pubitemid 44656902)
17. Müller-Scheweinitzer E. Pharmacodynamics and pharmacokinetics of dihydroergotamine (DHE) in conscious beagle dogs. Folia Haematol Int Mag Klin Morphol Blutforsch 1988;115:162-5
18. Fisher M, Gosy EJ, Heary B, Shaw M. Dihydroergotamine nasal spray for relief of refractory headache: a retrospective chart review. Curr Med Res Opin 2007;23:751-5 (Pubitemid 46631478)
19. Saper JR, Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: potential for a larger role. Headache 2006;46(Suppl 4):S212-20 (Pubitemid 44656906)
20. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62
21. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol 2009;16:968-81
22. Haag G, Diener HC, May A, et al. Self-medication of migraine and tension-type headache: summary of the evidence-based recommendations of the Deutsche Migräne und Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft für Neurologie (DGN), the Osterreichische Kopfschmerzgesellschaft (OKSG) and the Schweizerische Kopfwehgesellschaft (SKG). J Headache Pain 2011;12:201-17
23. Morren JA, Galvez-Jimenez N. Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?. Expert Opin Pharmacother 2010;11:3085-93
24. Cook RP, Shrewsbury SB, Ramadan NM. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs. IV DHE: potential mechanism. Headache 2009;49:1423-34
25. Shrewsbury SB, Cook RO, Taylor G, et al. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (Tempo™) inhaler. Headache 2008;48:355-67 (Pubitemid 351517766)
26. Le H, Tfelt-Hansen P, Russell MB, et al. Co-morbidity of migraine with somatic disease in a large population-based study. Cephalalgia 2011;31:43-64
27. Shrewsbury SB, Kori SH, Miller SD, et al. Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. Curr Med Res Opin 2008;24:1977-85
28. Aurora SK, Rozen TD, Kori SH, Shrewsbury SB. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache 2009;49:826-37
29. Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache 2011;51:507-17
30. Klapper JA, Staton J. Clinical experience with patient administered subcutaneous dihydroergotamine mesylate in refractory headaches. Headache 1992;32:21-3
31. Pringsheim T, Howse D. In-patient treatment of chronic daily headache using dihydroergotamine: a long-term follow-up study. Can J Neurol Sci 1998;25:146-50
32. Warner JS. The outcome of treating patients with suspected rebound headache. Headache 2001;41:685-92 (Pubitemid 32777751)
33. Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996;53(2):180-4 (Pubitemid 26055266)